Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
absence, ACIP, ADC, administered, Aldeyra, ASCO, avelumab, BAVENCIO, begun, BioSynapse, broad, Capitsol, carcinoma, CDC, chamber, chemoradiotherapy, clarified, crossover, death, Division, dry, EMA, ensifentrine, EQRx, group, IM, ISO, Kaigene, KGaA, marker, median, Medicinal, mm, nadir, obstructive, ocular, PDUFA, placebo, prespecified, pulmonary, Recerise, recruitment, redirecting, replacement, reproxalap, Schirmer, slightly, Subpart, superior, TECVAYLI, TIGIT, tolerability, traditional, unanimously, unresectable, urothelial, User, vehicle, Verona, women
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view